Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682723 | 0.87 | GRM5 (0.67) | GRM5POLBGPR119 | |
| SCHEMBL16682635 | 0.85 | GRM5 (0.48) | GRM5POLBGPR119NR1H2DTYMK | |
| SCHEMBL18200209 | 0.85 | GRM5 (0.47) | GRM5POLB | |
| SCHEMBL18183865 | 0.82 | GRM5 (0.44) | GRM5POLBGPR119NR1H2DTYMK | |
| SCHEMBL18183751 | 0.81 | NR1H2 (0.47) | GRM5POLBNR1H2MAPT | |
| SCHEMBL16682712 | 0.81 | GRM5 (0.58) | GRM5POLBGPR119 | |
| SCHEMBL12307404 | 0.80 | NR1H2 (0.48) | GRM5POLBNR1H2MAPT | |
| SCHEMBL23389957 | 0.80 | GRM5 (0.67) | GRM5NR1H2 | |
| SCHEMBL29796602 | 0.80 | GRM5 (0.67) | GRM5NR1H2 | |
| SCHEMBL16711314 | 0.79 | GRM5 (0.50) | GRM5NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | DRD4, DRD2, DRD3 | GRM5 185/4885POLB 3812/4885GPR119 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.